Navigation Links
Odyssey Thera to Participate in Expanded EPA Initiative
Date:12/6/2010

SAN RAMON, Calif., Dec. 6, 2010 /PRNewswire/ -- The United States Environmental Protection Agency (EPA) announced today a new phase of toxicity screening, in which 1,000 chemicals will be screened as part of EPA's ToxCast initiative. Odyssey Thera's participation in this program, first announced earlier this year, involves the application of extensive and diverse proprietary assay and screening technologies. "The Odyssey team is very pleased with our contributions to ToxCast to date, and we're excited to see this program accelerating," said Dr. Jane E. Lamerdin, Executive Director of R&D at Odyssey Thera, "ToxCast represents an ideal application of our validated chemical analysis strategies."

The chemicals will be assessed for potential toxicity to people and the environment. ToxCast is designed to determine how chemical exposures impact human biological processes and how the chemicals most likely lead to health effects. When fully implemented, ToxCast will be able to screen thousands of chemicals in fast, cost-effective tests that are relevant to human health. The chemicals being tested are found in industrial and consumer products, food additives and drugs that never made it to the market.

The full news release can be found at: http://yosemite.epa.gov/opa/admpress.nsf/d0cf6618525a9efb85257359003fb69d/73ec2518e34bc93d852577eb0060dd7c!OpenDocument. More information on ToxCast and the list of chemicals can be found at http://www.epa.gov/comptox.

About Odyssey Thera, Inc.

Odyssey Thera, Inc. is a privately held drug discovery technology company focused on improving the success rate of new therapeutic development. Odyssey Thera's technology measures disease–relevant pathway activity within living human cells. Odyssey is leveraging its proprietary drug discovery and development platform for internal programs and for premier pharmaceutical and biotechnology company partners. Patents owned by Odyssey also cover the use of the technology in live animals, plants and for diagnostic and bioprocess applications. To learn more about Odyssey Thera, please visit www.odysseythera.com.


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training
2. Stereotaxis and Siemens Promote Integrated Odyssey(TM) Solutions
3. Odyssey Thera Announces Achievement of Pfizer Drug Candidate Milestones
4. Nile Therapeutics Receives NASDAQ Notice; Will Request Hearing
5. Elekta Receives FDA 510(k) Clearance for XiO Software to Plan Spot Scanning for Proton Therapy
6. Halozyme Therapeutics Realigns Management
7. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
8. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
9. SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies
10. VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
11. Neuro Kinetics Receives HHS Therapeutic Discovery Grant to Further Research Into Early Diagnosis of Sports Concussions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017 Executive ... through extensive primary research (inputs from industry experts, ... to present the analysis of global heart valve ... and Repair); Replacement Procedure By Technique (Mechanical, Bioprosthetic, ... (Surgical Devices, Balloon Valvuloplasty, Transcatheter Mitral Valve Repair ...
(Date:3/23/2017)... March 23, 2017 As a result ... with the prevalence of allergic diseases, cutting edge ... currently revolutionising the ways in which pharmaceutical and ... 2017 promises to be both a high quality ... allergy interest groups, immunologists, research scholars and doctors. ...
(Date:3/23/2017)... , March 23, 2017 ... and Healthcare disease pipeline guide Primary Hyperoxaluria - ... the Primary Hyperoxaluria (Genito Urinary System And Sex ... rare condition characterized by recurrent kidney and bladder ... substance called oxalate. Symptoms include blood in the ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... enhancements, upgrading their training and leads programs. , In February, 2017, Empower Brokerage ... sales agents, Performance Partners is designed to teach how to maximize their sales ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
(Date:3/23/2017)... ... 2017 , ... A recent report from the National Council on Teacher Quality ... report suggests, based on a review of GPA and SAT/ACT requirements at 221 institutions ... U.S. It argues that this higher bar should be set by states, by the ...
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd ... at 10 North Broadway Avenue, will be an educational and exciting program providing ... in the management of chronic pain. , Oklahoma is in a healthcare crisis. ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... firm serving the families and businesses of the Norwalk and Vermillion areas, ... Ohio Recovery Center (N.O.R.A.) is a nonprofit, community-based substance abuse prevention and ...
Breaking Medicine News(10 mins):